The resignation of Food and Drug Administration (FDA) commissioner Scott Gottlieb adds further uncertainty to the future of federal oversight of CBD in the US ...
Written by Freddie Dawson || 7th March 2019 || Regulatory briefing |
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
